[1] Arber DA, Orazi A, Hasserjian R, et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood,2016, 127(20):2391-2405.
[2] Papaemmanuil E, Gerstung M, Bullinger L, et al.Genomic Classification and Prognosis in Acute Myeloid Leukemia[J]. N Engl J Med,2016,374(23):2209-2221.
[3] Metzeler KH, Herold T, Rothenberg-Thurley M, et al.Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia[J]. Blood,2016,128(5):686-698.
[4] Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations[J]. Blood.2015 Feb 26;125(9):1367-1376.
[5] Döhner H, Estey E, Grimwade D, et al.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel[J]. Blood,2017, 129(4):424-447.
[6] Shafer D, Grant S.Update on rational targeted therapy in AML[J]. Blood Rev,2016,30(4):275-283.
[7] Welch JS, Petti AA, Miller CA, et al.TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes[J]. N Engl J Med,2016,375(21):2023-2036.
[8] Ivey A, Hills RK, Simpson MA, et al.Assessment of mini-mal residual disease in standard-risk AML[J]. N Engl J Med,2016,374(5):422-433. |
